Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia - Manuela, MX Tan; Raquel, Real; Michael, A Lawton; Catherine, Bresner; Kanavou, Sofia; Foltynie, Thomas; Nicholas, W Wood; Mike, A. Nalls; Nigel, M Williams; Yoav, Ben-Shlomo; Michele, TM Hu; Donald, G Grosset; et al. (medRxiv, 2021)
In their recent letter entitled “Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in parkinson’s disease”, Liu and colleagues report that in a genome-wide analysis of progression to dementia in parkinson’s disease (PD) the RIMS2 locus is a determinant of dementia in PD (1). In this study we have evaluated the nominated loci in a well-powered longitudinal clinical-genetic study of 2536 individuals in the tracking parkinson’s and oxford discovery cohorts. We have not identified any association between the RIMS2 locus or other loci from the discovery phase and the development of Parkinson’s dementia. further work is needed to understand the biological determinants of this important aspect of parkinson’s and to guide the search for new treatments.Brief paragraph/Abstract In their recent letter entitled “Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease”, Liu and colleagues report that in a genome-wide analysis of progression to dementia in Parkinson’s disease (PD) the RIMS2 locus is a determinant of dementia in PD (1). In this study we have evaluated the nominated loci in a well-powered longitudinal clinical-genetic study of 2536 individuals in the Tracking Parkinson’s and Oxford Discovery cohorts. We have not identified any association between the RIMS2 locus or other loci from the discovery phase and the development of Parkinson’s dementia. Further work is needed to understand the biological determinants of this important aspect of Parkinson’s and to guide the search for new treatments.Competing Interest StatementM.M.X.T is supported by Parkinson UK M.A.N. participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research, he also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc as a data science fellow. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number ZO1 AG000535, as well as the National Institute of Neurological Disorders and Stroke. J.H. is supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer Society, and Alzheimer Research UK. He is also supported by the MRC, Wellcome Trust, Dolby Family Fund, National Institute for Health Research University College London Hospitals Biomedical Research Centre. Y.B.-S. has received grant funding from the MRC, NIHR, Parkinson UK, NIH, and ESRC. N.M.W. is supported by Parkinson UK. M.T.H. receives grants from Parkinson UK, Oxford NIHR Biomedical Research Centre, and MJFF and is an adviser to the Roche Prodromal Advisory and Biogen Digital advisory boards. D.G.G. has received grants from Michael's Movers, the Neurosciences Foundation, and Parkinson's UK, and honoraria from BIAL Pharma, GE Healthcare, and consultancy fees from Acorda Therapeutics and the Glasgow Memory Clinic. H.R.M. reports paid consultancy from Roche. Research Grants from Parkinson UK, Cure Parkinson Trust, PSP Association, CBD Solutions, Drake Foundation, Medical Research Council, Michael J Fox Foundation. Dr Morris is a co-applicant on a patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140) All other authors did not declare any funding sources that directly contributed to this study. M.M.X.T. takes responsibility for the integrity of the data and the accuracy of the data analysis. Funding StatementCohort studies: Both Tracking Parkinson's and Oxford Discovery are primarily funded and supported by Parkinson's UK. Both studies are supported by the National Institute for Health Research (NIHR) Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). Oxford Discovery is also supported by the NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust, and the University of Oxford. This research was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The UCL Movement Disorders Centre is supported by the Edmond J. Safra Philanthropic Foundation. Genetic analysis: Work on the genetics of progression in Parkinson's is supported by Parkinson's UK (PhD Studentship to Dr Tan H-1703, Understanding and predicting Parkinson's progression) and by Aligning Science Across Parkinson's [Grant ID: ASAP 0478] through Michael J. Fox Foundation for Parkinson's Research (MJFF) (Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815). For the purpose of open access, the author has applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Tracking Parkinson's has multi-centre research ethics approval West of ScotlandResearch Ethics Committee: IRAS 70980, MREC 11/AL/0163, Clinicaltrials.gov: NCT02881099). Oxford Discovery has multi-centre research ethics approval (South Central Oxford A Research Ethics Committee 16/SC/0108 ). Each subject provided written informed consent for participation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability: The original data used in this study is available from the Tracking Parkinson’s (www.trackingparkinsons.org.uk) and Oxford Discovery teams (www.dpag.ox.ac.uk/opdc) Code and method availability: The analysis protocol, code and full summary statistics are available at GitHub (https://github.com/huw-morris-lab/dementia_GWAS_replication; doi: 10.5281/zenodo.5137374) https://doi.org/10.5281/zenodo.5137374